Deal Smooths Japan Entry For Portola’s Factor Xa Antidote
This article was originally published in PharmAsia News
Executive Summary
Pfizer and BMS are to develop Portola's anticoagulant reversal agent in Japan in a $100m-plus deal that is set to bring the first-in-class product to the major Japanese market. Bayer will also participate in a local clinical program.